Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan.
Department of Chinese Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, No. 707, Sec. 3, Chung-Yang Rd., Hualien, Taiwan, 970.
BMC Complement Med Ther. 2020 Mar 30;20(1):100. doi: 10.1186/s12906-020-02894-8.
Few studies have evaluated the association between the risk of coronary artery disease (CAD) and the use of Chinese herbal products (CHP) in patients with rheumatoid arthritis (RA). This study investigated the risk of CAD among patients with RA using CHP in combination with conventional medicine.
A retrospective cohort study was conducted using the Taiwan National Insurance Research Database to assess 22,353 patients who had been newly diagnosed with RA between 1997 and 2010. Patients were assigned to the CHP group or non-CHP group according to their use or nonuse of CHP after being diagnosed with RA. The Cox proportional hazards model was used to estimate the hazard ratio (HR) of CAD for a 1:1 matched sample.
Both the CHP and non-CHP groups comprised 4889 patients after 1:1 matching. The risk of CAD was significantly reduced in the CHP group [adjusted HR (aHR): 0.59, 95% confidence interval (CI): 0.50-0.71] compard with the non-CHP group. Those who used CHP for > 180 days had an even lower risk of CAD than users with CHP usage less than 30 days (aHR: 0.64, 95% CI: 0.43-0.95). Additionally, frequently prescribed formulae, such as Kuei-Chih-Shao-Yao-Chih-Mu-Tang, Tang-Kuei-Nien-Tung-Tang, and Shu-Ching-Huo-Hsieh-Tang, were associated with a reduced risk of CAD.
The use of CHP was associated with a lower risk of CAD in patients with RA. Additional randomized controlled trials are required to assess any causal relationship between the effect of CHP usage and the risk of CAD.
鲜有研究评估了类风湿关节炎(RA)患者使用中草药(CHP)与冠心病(CAD)风险之间的关系。本研究调查了同时使用 CHP 和常规药物的 RA 患者发生 CAD 的风险。
使用台湾全民健康保险研究数据库进行回顾性队列研究,评估了 1997 年至 2010 年间新诊断为 RA 的 22353 例患者。根据患者确诊 RA 后是否使用 CHP,将其分为 CHP 组或非 CHP 组。使用 Cox 比例风险模型估计 CAD 的风险比(HR)。
1:1 匹配后,CHP 组和非 CHP 组各有 4889 例患者。与非 CHP 组相比,CHP 组的 CAD 风险显著降低[校正 HR(aHR):0.59,95%置信区间(CI):0.50-0.71]。与 CHP 使用少于 30 天的患者相比,使用 CHP 超过 180 天的患者 CAD 风险更低(aHR:0.64,95%CI:0.43-0.95)。此外,常用方剂如归芪少遥知母汤、当归拈痛汤和疏风清热汤与 CAD 风险降低相关。
RA 患者使用 CHP 与 CAD 风险降低相关。需要进行更多的随机对照试验来评估 CHP 使用效果与 CAD 风险之间的因果关系。